A Multi-center, Randomized, Double-blinded, Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease.

Trial Profile

A Multi-center, Randomized, Double-blinded, Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Crohn's disease; Fistula
  • Focus Registrational; Therapeutic Use
  • Acronyms IMAgINE 1; IMAgINE-1
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 19 May 2016 Results from this trial will be presented at the Digestive Disease Week (DDW) Annual Meeting 2016, according to an AbbVie media release.
    • 02 May 2016 This trial is prematurely ended in Italy.
    • 04 Apr 2016 Results published in an AbbVie media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top